Macrophages Inhibit Neovascularization in a Murine Model of Age-Related Macular Degeneration
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 y of age in at least three continents. Choroidal neovascularization (CNV) is the process by which abnormal blood vessels develop underneath the retina. CNV develops in 10% of patients with AMD but accounts for up to 90% of the blindness from AMD. Although the precise etiology of CNV in AMD remains unknown, the macrophage component of the inflammatory response, which has been shown to promote tumor growth and support atherosclerotic plaque formation, is thought to stimulate aberrant angiogenesis in blinding eye diseases. The current theory is that macrophage infiltration promotes the development of neovascularization in CNV. METHODS AND FINDINGS: We examined the role of macrophages in a mouse model of CNV. IL-10(-/-) mice, which have increased inflammation in response to diverse stimuli, have significantly reduced CNV with increased macrophage infiltrates compared to wild type. Prevention of macrophage entry into the eye promoted neovascularization while direct injection of macrophages significantly inhibited CNV. Inhibition by macrophages was mediated by the TNF family death molecule Fas ligand (CD95-ligand). CONCLUSIONS: Immune vascular interactions can be highly complex. Normal macrophage function is critical in controlling pathologic neovascularization in the eye. IL-10 regulates macrophage activity in the eye and is an attractive therapeutic target in order to suppress or inhibit CNV in AMD that can otherwise lead to blindness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 IL-10 and Neovascularization (CNV) (A and B) CNV was induced in IL-10 −/− (volume of the neovascular complex: 829.6 ± 225.7 μm3) and B6 (IL-10 +/+; 8,830.7 ± 1,130.3 μm3) mice (A) and B6 mice injected on days 0, 3, and 5 with anti-IL-10 (10,115.3 ± 850.5 μm3) or isotype control antibody (IgG2b; 33,602.3 ± 317.4 μm3) (B). Asterisks indicate values significantly different from control; p-values given in parentheses are based on Student's t test performed as described [17,18]. (C and D) Seven days following laser treatment, the volumes of the neovascular complexes (green) were determined by confocal microscopy. Shown is representative CNV in a B6 eye (C) and an IL-10 −/− eye (D).](https://figures.cochat.ai/paper-figures/cde3ba67c69c474c99ccd1b8774a91be/macrophages-inhibit-neovascularization-in-a-murine-model-of-age-related-macular-figure-1.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“On the other hand, Apte and colleagues, using a model of interleukin-10 (IL-10) deficient mice, found that macrophages play a protective role in CNV (Apte et al., 2006).”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Apte et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737
Complement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
Prevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449 · cited 1×
“Recent genetic-linkage-based evidence suggests the potential importance of complement factor H in AMD [9,11,12].”
BackgroundComplement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424 · cited 1×
“Recent genetic-linkage-based evidence suggests the potential importance of complement factor H in AMD [9,11,12].”
BackgroundPegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 3×
“The model has also been used in preclinical trials for testing potential therapies for AMD that have since proven effective in preventing vision loss [16,27].”
BackgroundMethod(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 1×
“Current estimates of patients affected with AMD are higher than those of patients affected by Alzheimer disease [8].”
Result
Research works printed but not linked: 42
- Nakao, 2005, J Clin Invest, 115, 2979
- Taylor, 2005, Annu Rev Immunol, 23, 901
- Hansson, 2005, N Engl J Med, 352, 1685
- Sakurai, 2003, Invest Ophthalmol Vis Sci, 44, 3578
- Espinosa-Heidmann, 2003, Invest Ophthalmol Vis Sci, 44, 3586
- van Leeuwen, 2003, Eur J Epidemiol, 18, 845
- Klein, 2004, Am J Ophthalmol, 137, 486
- Hebert, 2003, Arch Neurol, 60, 1119
- Edwards, 2005, Science, 308, 421
- Hageman, 2005, Proc Natl Acad Sci U S A, 102, 7227
- Haines, 2005, Science, 308, 419
- Klein, 2005, Science, 308, 385
- Ambati, 2003, Nat Med, 9, 1390
- Lobov, 2005, Nature, 437, 417
- Bressler, 2001, Arch Ophthalmol, 119, 198
- Gragoudas, 2004, N Engl J Med, 351, 2805
- Kaplan, 1999, Nat Med, 5, 292
- Apte, 2004, Invest Ophthalmol Vis Sci, 45, 4491
- Miller, 1995, Arch Ophthalmol, 113, 810
- Adamis, 1996, Arch Ophthalmol, 114, 66
- Mori, 2002, Invest Ophthalmol Vis Sci, 43, 1994
- Campochiaro, 2006, Hum Gene Ther, 17, 167
- Ferguson, 1994, J Exp Med, 179, 1597
- Inaba, 1992, J Exp Med, 176, 1693
- Marmorstein, 2000, Proc Natl Acad Sci U S A, 97, 12758
- Wiley, 2001, Immunity, 15, 837
- Moore, 2001, Annu Rev Immunol, 19, 683
- Gordon, 1995, J Neuroimmunol, 62, 153
- Brown, 1999, J Immunol, 162, 480
- Diegelmann, 2004, Front Biosci, 9, 283
- Park, 2004, Am J Surg, 187, 11S
- Friedman, 2004, Arch Ophthalmol, 122, 564
- VanNewkirk, 2000, Ophthalmology, 107, 2203
- Bonastre, 2002, Eur J Health Econ, 3, 94
- Miskala, 2004, Arch Ophthalmol, 122, 758
- Papadimitriou, 2000, J Drug Target, 8, 335
- Krasnici, 2003, Int J Cancer, 105, 561
- Penfold, 2001, Prog Retin Eye Res, 20, 385
- Grossniklaus, 2005, Arch Ophthalmol, 123, 914
- Grossniklaus, 2006, Am J Ophthalmol, 141, 93
- Kuo, 2000, Int Ophthalmol Clin, 40, 111
- Gomez, 2005, Curr Opin Immunol, 17, 457
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
“, 2015), and factors associated with abnormal activation of monocyte derived macrophages and glial cells as they age (Apte et al., 2006; Ban et al., 2018; Combadière et al., 2007; Kelly et al., 2007; Ma and Wong, 2016; Sene et al., 2013).”
BackgroundSelf-citationBhutto, I., & Lutty, G. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.04.005 · Cited by 1,005
“Interleukin-2, -6, and -10 might participate to CNV expansion, but their exact roles have not been investigated thoroughly yet (Apte et al., 2006; Izumi-Nagai et al., 2007).”
BackgroundMolecular pathology of age-related macular degeneration
Ding, X., Patel, M., & Chan, C.-C. (2009) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.10.001 · Cited by 582
“might therefore be secondary to the direct injury to CNV endothelium, rather than the depletion of macrophages (Apte et al., 2006).”
BackgroundInfluentialImmunology of age-related macular degeneration
Ambati, J., Atkinson, J. P., & Gelfand, B. D. (2013) · Nature Reviews Immunology · doi:10.1038/nri3459 · Cited by 584
Macrophages and lipid metabolism
Remmerie, A., & Scott, C. L. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.01.020 · Cited by 433
Metadata
- Authors
- Apte, R. S., Richter, J., Herndon, J., & Ferguson, T. A.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Apte, Rajendra S
- Ferguson, Thomas A
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2006-08-15
- Volume
- 3
- Issue
- 8
- Pages
- e310
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC1539093
- OpenAlex
- W2000383031
- Cited by
- 249
- References
- 45
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 10 · 2023: 11 · 2022: 8 · 2021: 18 · 2020: 18 · 2019: 11 · 2018: 19 · 2017: 10 · 2016: 12 · 2015: 16 · 2014: 15 · 2013: 19 · 2012: 12
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Research to Prevent Blindness
- National Institutes of Health (5p60dk020579-35, 5r01ey008972-07, DK20579, P60-DK-20579, 5 P60 DK20579, EY06765)
- National Eye Institute (EY08972, EY 12826, K08EY016139, R01EY012826, F32EY006765, EY06765, R01EY006765)
- National Institute of Diabetes and Digestive and Kidney Diseases (5P60 DK20579, P60-DK-020579)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- age-related macular degeneration, choroidal neovascularization, macrophages, IL-10, Fas ligand, angiogenesis, choroidal inflammation, macrophage infiltration, therapeutic target
- MeSH terms
- Aging, Animals, Disease Models, Animal, Injections, Macrophages, Macular Degeneration, Mice, Inbred C57BL, Mice, Transgenic, Molecular Sequence Data, Retina, Interleukin-10, Cell Death, Choroidal Neovascularization, Mice, Fas Ligand Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Macrophages Inhibit Neovascularization in a Murine Model of Age-Related Macular Degeneration. https://app.cochat.ai/papers/10.1371/journal.pmed.0030310
- The paper
- Apte, R. S., Richter, J., Herndon, J., & Ferguson, T. A. (2006). Macrophages Inhibit Neovascularization in a Murine Model of Age-Related Macular Degeneration. PLoS Medicine. https://doi.org/10.1371/journal.pmed.0030310
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.